Targets › ASNS
6 programs from 6 companies in 9 trials: 4 Phase 1, 4 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Catalyzes the ATP-dependent synthesis of L-asparagine from L-aspartate, using L-glutamine as a source of nitrogen. Can also use ammonia as the nitrogen source in vitro. (UniProt, P08243)
Open in Phaseline: the race on ASNS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | pegaspargase PEGylated asparaginase depletes asparagine to induce leukemic cell death | ASNS | Phase 3 | Acute Lymphoblastic Leukemia | Mar 2027 |
| Peking University Cancer Hospital & Institute | Pegaspargase Asparagine synthetase inhibitor (PEGylated asparaginase) | ASNS | Phase 2 | NK/T Cell Lymphoma | Dec 2026 |
| Dana-Farber Cancer Institute | Neo Vax Pegylated asparaginase (calaspargase pegol) | ASNS | Phase 2 | Acute Lymphoblastic Leukemia; Breast Cancer Female; Follicular Lymphoma; Non-small Cell Lung Cancer | Dec 2026 |
| M.D. Anderson Cancer Center | Calaspargase pegol-mknl Asparaginase analog; depletes asparagine | ASNS | Phase 2 | T-cell Acute Lymphoblastic Leukemia | Dec 2029 |
| Mingzhi Zhang | Pegaspargase PEGylated asparaginase that depletes asparagine | ASNS | Phase 1 | NKTCL | Dec 2026 |
| H. Lee Moffitt Cancer Center and Research Institute | Calaspargase Pegol Asparaginase pegol - depletes serum asparagine | ASNS | Phase 1 | Acute Lymphoblastic Leukemia | – |
Acute Lymphoblastic Leukemia (3) T-cell Acute Lymphoblastic Leukemia (1) NK/T Cell Lymphoma (1) NKTCL (1) Breast Cancer Female (1) Follicular Lymphoma (1) Non-small Cell Lung Cancer (1)
mixed (3), protein or peptide (2), small molecule (1)
H. Lee Moffitt Cancer Center and Research Institute (1) M.D. Anderson Cancer Center (1) Peking University Cancer Hospital & Institute (1) Mingzhi Zhang (1) Assistance Publique - Hôpitaux de Paris (1) Dana-Farber Cancer Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.